1 / 66

HYPERTENSION ABC & Update

HYPERTENSION ABC & Update. Mahmoud Khattab, Ph.D. Professor of Pharmacology & Toxicology. Development of Structural and Functional Alterations in the Hypertensive Vessel Wall. Smooth Muscles & Endothelial Morphologic Changes In Hypertension.

zorana
Download Presentation

HYPERTENSION ABC & Update

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. HYPERTENSIONABC & Update Mahmoud Khattab, Ph.D. Professor of Pharmacology & Toxicology

  2. Development of Structural and Functional Alterations in the Hypertensive Vessel Wall

  3. Smooth Muscles & Endothelial Morphologic Changes In Hypertension • The smooth muscle content of arteries can be augmented by an increase in cell number (hyperplasia) or an increase in cell mass (hypertrophy) • The volume of the endothelial cells increases and the surface configuration becomes more globular, so that the cells protrude into the lumen of the vessel

  4. Linkage Between Structural & Functional Changes Poiseuille’s Law: Resistance α 1/r4

  5. Possible mechanisms of Apparent Increased Sensitivity to Vasoconstrictors Patients with essential hypertension have apparent increased sensitivity to forearm infusion of norepinephrine (0.40 μg/min) (increase in resistance) • True increased sensitivity to vasoconstrictors  • Increased receptor sensitivity • Increased activation of second messengers or ion channels • Apparent increased sensitivity due to effects of structure or function to increase resistance  • Hypertrophy or hyperplasia • Decreased endothelial-dependent vasodilator mechanisms

  6. Characteristics of Hypertension • Elevated BP at maintained cardiac output • Interaction of environmental and genetic factors • Both structural and functional changes in arterioles leading to increased resistance • Structural changes resulting from growth or remodeling of the vessel due to the positive influence of growth factors or the removal of growth inhibitors • Functional abnormalities involving endothelial and vascular smooth muscle dysfunction • Abnormalities in membrane ionic control mechanisms likely underlying abnormalities in both contraction and growth • Enhanced vascular responsiveness to vasoconstrictors

  7. AHA Classification

  8. Classification and Goal JAMA 2003;289:2560–2572 • The seventh Report of the Joint National Committee on Detection, Evaluation, and Treatment of High BP (JNC 7)classified hypertension as in the given table • A clinical HTN is based upon two or more seated BP measurements on two more occasions • Ultimate GOALs: • Decrease BP • Reduce associated morbidity manifested as TARGET-ORGAN DAMAGE • CVS risk factors increase frequency of target organ damage (HP+LVH: CHF)

  9. Hypertension -related Target Organ Damage • Brain: stroke/transient ischemic attack • Eyes: retinopathy • Heart: LV hypertrophy, HF, angina • Kidney: chronic kidney disease • Peripheral vasculature: peripheral arterial disease

  10. Heart Promoting atherosclerotic changes (indirectly) Pressure-related: Enhancement of CVD Increase risk for IHD (angina & MI) Antihypertensive therapy reduce such risks Enhance the progress of LVH (LVH+HP; Framingham Study: Increased CHF) BRAIN HTN frequently leads to cerebro-vascular disease as: Transient ischemic attacks Ischemic strokes Cerebral infarcts Antihypertensive therapy reduce the risk of initial and recurrent stroke Hypertension -related Target Organ Damage

  11. Hypertension -related Target Organ Damage Kidney • HP leads to increased intraglomerular pressure causing nephrosclerosis • HTN-Kidney lesion, What comes first? • Chronic kidney disease can proceed to kidney failure (dialysis) • Moderate (Stage 3) Kidney disease (GFR 30-59 mL/min) indicates target organ damage (Creatinine 1.3-1.5 mg/dL) • Albuminurea (>300 mg/day or 200 mg albumin/g creatinine) indicates target organ damage

  12. Peripheral Arterial Disease An atherosclerotic vascular disease equivalent in risk to CAD BP reduction, risk factor modification & antiplatelets are needed to stop progress Complications can attain infection & necrosis EYE Hypertension can induce retinopathy that may proceed to blindness G 1: arterial vasoconstriction G2: Arteriovenous nicking (atherosclerosis) G3: Cotton wool exudates & hemorrhage (untreated HP or accelerated Hypertension -related Target Organ Damage

  13. Major CVS Risk Factors • Age: more than 55 years men, 65 years women • Cigarette smoking • Diabetes mellitus • Hypertension • Dyslipedimia • Obesity • Physical inactivity • Kidney disease: GFR ≤60mL/min

  14. CVS Risk versus BP • Direct correlation between risk of CVD & BP values (epidemiological studies) • Above 115/75 mm Hg, with each increment of 20/10 mm Hg, the risk of CVD doubles • Pre-hypertensive patients are at higher CVD risk than normal • Clinically, elevated SBP is a more predictor of CVD than elevated DBP in patients over 50 years

  15. BP Numerical Values Goal • In most patients, the target BP value is reduce BP lower than 140/90 mm Hg • In diabetic patients and chronic kidney disease patients (estimated GFR ≤60 mL/min or albumin-urea), Coronary Artery Disease (CAD): BP goal is less than 130/80 mm Hg • In LV dysfunction, goal BP is <120/80 • These patients are at high risk for target organ damage

  16. Hypertension Misconceptios • Stress-related: Apart from white coat HP, most HP patients have elevated BP independent of their stress status • Headache (and other symptoms) have no correlation with hypertension • Hypertension though asymptomatic, it has serious long-term complications; long-term therapy • Stress management is not that beneficial in controlling HP • Clinically evidenced, a better quality of life with proper medication; drugs are NOT worsening quality of life

  17. Patient Evaluation/Risk Assessment • Absence or presence of various forms of hypertension-related target organ damage • Identifiable (secondary) causes of hypertension • Concomitant major CV risk factors, other disorders, and assessment of lifestyle habits

  18. HYPERTENSION THERAPYLifestyle Modification • For BP lowering & reduction of CV risk • In prehypertensives: lifestyle modification leads to BP lowering + inhibition or minimizing HTN progress • Possible reduction of dose and/or No of antihypertensive drugs used PATIENT EDUCATION IS NEEDED

  19. Weight Reduction 5-10% wt reduction in overweight persons may lower CV risk For every 1 kg wt loss, there is lowering of SBP & DBP by 2.5 & 1.5 mm Hg respectively DASH Diet Dietary Approaches to Stop Hypertension (DASH) diet is rich in fruits, vegetables & low-at dairy foods, combined to less saturated & total fat A 8-14mm Hg reduction in SBP can be produced Lifestyle Modification

  20. DASH Diet

  21. Dietary Sodium Restriction Epidemiology: positive correlation between BP and sodium intake Trials: 2-8 mm Hg reduction in SBP on restricted sodium diet ≤ 2.4 g/day Physical Activity There is 4-9mm Hg reduction in SBP in most patients upon regular PA HTN patients with compromised CVD need medical evaluation before PA Physical activity: at least 30 min for 3-5 days/week Walking, running, cycling, swimming Lifestyle Modification

  22. Smoking Cessation The most important modifiable CV risk factor Cigarette smoking increases CV & total mortality, cessation lowers CVD incidence It interferes with response to some drugs (β blockers) Patient education Unproven Modifications High levels of K+, Ca2+, & Mg2+ relate to lower BP, no reduction of CV risk K+& Mg2+ intake in HP/chronic renal disease may be harmful (cardiac toxicity) Caffeine drinks limitation is not essential unless for other medical reason Lifestyle Modification

  23. Algorithm for Treatment of Hypertension Beta-blockers not first-line in AHA guidelines 2007

  24. Patient Education About Treatment • Assess patient’s understanding and acceptance of the diagnosis of hypertension • Discuss patient’s concerns and clarify misunderstandings • Tell patient BP reading and provide a written copy • Come to agreement with the patient on goal BP • Ask patient to rate (1 to 10) his or her chance of staying on treatment • Inform patient about recommended treatment and provide specific written information about the role of lifestyle, including diet, physical activity, dietary supplements, and alcohol intake; use standard brochures when available • Emphasize: •  Need to continue treatment •  Control does not mean cure •  One cannot tell if BP is elevated by feeling or symptoms; BP must be measured

  25. Evidence-Based Hypertension TherapySELECTION • JNC7 drug therapy algorithm follows evidence-based approach linked to clinical trials interpretation • Thiazide-type diuretic-based therapy leads to significant reductions in: • Stroke (25-47%), Heart attacks (13-27%), All-cause CVD (17-40%), & Survival improvement • Systolic Hypertension in Elderly Program (SHEP), • Swedish Trial of Old Patients with Hypertension (STOP-hypertension) • Medical Research Council (MRC)

  26. Thiazide-Based Therapy versus Newer Agents (The ALLHAT study) • Several clinical trials using newer agents (ACE inhibitors, ARBs, and CCBs) found reduction of BP and CV risk in a similar to thiazides • Possibly ACEIs having better effects • The 2007 AHA HTN guidelines are now the most recent for treatment (Circulation 2007, 115: 2761)

  27. Algorithm for Treatment of Hypertension Beta-blockers NOT 1st line in 2007 AHA guidelines

  28. The ALLHAT Study • The Antihypertensive & Lipid Lowering Treatment to prevent Heart Attack Trial provides recent evidence for thiazide efficacy as used by JNC7 • Designed to testify hypothesis of superiority of newer drugs: amlodipine, doxazosin & lisinopril over the thiazide diuretic chlorthalidone • End-point: combined fatal CHD & non-fatal MI • 42,418 patients for a mean of 4.9 years • Doxazosin arm prematurely terminated because of increased HF risk

  29. The ALLHAT Study • Outcome: No significant difference between chlorthalidone and either amlodipine or lisinopril as regards combined end point • Secondary endpoints pointed to better efficacy of thiazide over amlodipine (less HF) and lisinopril (less combined CVD, HF, & stroke) • Investigators concluded superiority of thiazide diuretics or at least unsurpassed activity • A 2003 network meta-analysis of 42 clinical trials found that low-dose diuretic were most effective first-line treatment for prevention CVD & mortality JAMA;289: 2534 (2003)

  30. Hypertension with Compelling Indications

  31. Starting Drug Therapy • MONOTHERAPYwhen INITIAL BP IS CLOSE TO GOAL VALUE, 15-20 mm Hg SBP & 10 mm Hg DBP (JNC 7 & others) • STEPPED CARE, • A single drug is chosen & dose increased till BP control occurred, max dose reached, or dose-limiting toxicity • A second drug from a different class is added

  32. Starting Drug Therapy SEQUENTIAL THERAPY • If goal BP is not achieved an alternative drug is chosen, to replace an initial one • It is more advised when the initial drug is not well tolerated or achieved poor BP efficacy Combination Therapy • Encouraged for patients stage 2 hypertension or far from BP goal • Initial combination therapy can be useful for chronic renal disease/diabetes/other resistant patients

  33. THERAPY MONITORING • Four aspects are considered upon monitoring: • BP control evaluated 1-4 weeks after therapy initiation/modification • Initial BP lowering needs 1-2 weeks, but steady BP up to 4 weeks • Average of 2 measurements is used • Standing BP measurement for orthostatic hypotension evaluation (whenever dizziness occurs) • Compliance (adherence) • Progression of the disease; target-organ damage points to therapy modification • Toxicity

  34. Diuretics Thiazides • Are diuretic of choice achieving goal BP values in 50-80% of patients • Hydrochlorthiazide (HCTZ) & chlorthalidone are the most frequently used • Dose of 12.5-25 mg once daily can lower SBP by 15-20 mm Hg & DBP 8-15 mm Hg • Low-dose therapy is equi-effective for both agents according to huge clinical evidence

  35. Diuretics Loop Diuretics • HCTZ is more effective than loop diuretics though less potent • Furosemide is the most frequently used agent, but given more than once daily • They are diuretics of choice in hypertensive patients with severe kidney disease or failure (creatinine 2.5-3 mg/dL) • They are preferred in patients with CHF or severe edema

  36. Diuretics K+-sparing Diuretics • Amiloride/triametrene are reserved for patients developing diuretic-induced hypokalemia • Fixed-dose products including HCTZ & K+-sparing diuretic are available, but initial usage to avoid hypokalemia is not rationalized • They have modest antihypertensive effect when used as monotherapy

  37. Diuretics Aldosterone Receptor Antagonists • Spironolactone & eplerenone cause hyperkalemia, especially in chronic renal disease • Eplerenone is more specific, less gynecomastia but causes greater hyperkalemia • Eplerenone is contraindicated in patients at high risk of hyperkalemia including diabetic 2 patients/albuminurea • Spironolactone is beneficial in hypertensive patients with CHF where it reduces morbidity & mortality • Eplerenone reduces mortality in HF & LV failure in early post MI patients

  38. DiureticsSide-Effects

  39. β-Adrenoceptor Blockers • β-Blockers reduce morbidity & mortality in hypertensive patients with compelling indications; CHF, post-MI, high-risk CHD, & diabetes • All β-Blockers have similar activity on BP lowering • Incidence of side-effects is low in practice and is dose-dependent, i.e., can be minimized with low- to moderate-doses

  40. Pharmacologic Characteristics of β-Blockers NO-Donotaing

  41. Hemodynamic Response to β-Adrenoceptor Blockade • BP decrease after acute response) is modest, with continued treatment the BP decrease becomes much larger in most patients • The magnitude of the decrease in heart rate and cardiac output and the reactive increase in PVR vary with the degree of ISA • These responses do not account for the long-term decrease in BP

  42. Adverse Effects of β-Adrenoceptor Blockers

  43. β-Blockers • Nonselectiveβ-Blockers are preferred in patients with non-CV indications like migraine prophylaxis/tremor • ISA β-Blockers are indicated for patients responding with severe bradycardia to non-ISA β-blockers • ISA β-Blockers should be avoided in patients with MI history where agonistic properties may worsen the cardiac function

  44. β-BlockersLipid Solubility • Lipid solubility is of max clinical relevance in patients with renal/hepatic impairment • High lipid sol drugs like propranolol are hepatically cleared • Hydrophilic ones (atenolol) have main renal excretion (require dose adjustment) • Lipophilic agents are probably associated with increases CNS side effects like nightmares, depression • High lipid soluble drugs are desirable for migraine prophylaxis due to better CNS access

  45. β-BlockersCompelling Indications • Heart failure (systolic); metoprolol & carvedilol are approved with reduced CV morbidity & mortality • Start with LOW DOSE & gradually increase it • Post-MI & acute MI patients (including relatively contraindicated ones) have prolonged survival & reduced re-infarction • High-Risk CHD: HTN patients with chronic angina or acute CHD (non-ST segment elevation MI & unstable angina) may proceed to fatal MI or others • Decreased HR, contractility & myocardial O2 demand produced by β-blockers reduce the risk

  46. β-BlockersCompelling Indications • Diabetes; a cardio-selective agent is preferred • β-Blockers decrease coronary events, the renal disease progression, and stroke in diabetics • All agents can mask symptoms of epinephrine-associated hypoglycemia (tremors, hunger & palpitations) but not sweating • They cause insulin release inhibition • Non-selective agents can worsen hypoglycemia & prolong recovery from hypoglycemia • β-Blockers are best avoided in Type 1 diabetes but hypoglycemic effects are less common in Type 2 • Non-selective agents should be avoided in “brittle” diabetics especially insulin-dependent patients

  47. ACE InhibitorsEffects of Chronic ACE Inhibition on theRAA System • AngiotensinII disappears from the circulation at peak ACE block • Plasma renin activity, active & inactive renin concentrations increase • The hyperreninemia leads to a rise in plasma angiotensin I levels • The plasma levels of aldosterone are reduced during ACE inhibition • There is an induction of ACE synthesis during long-term treatment

  48. ACE InhibitorsClinical Pharmacological Profile • ACEIs lower BP via peripheral vasodilation with no alteration of CO/HR/or GFR through RAA system &increased vasodilating bradykinin & PGs • Beneficial effects include correction of endothelial dysfunction, LVH regression, insulin sensitivity improvement & collateral vessel development • They can raise serum K+ especially in renal impairment patients • Acute renal compromise in patients with bilateral renal stenosis can occur • Modest creatinine rise, NOT discontinue ACEIs

  49. ACE InhibitorsRisk of Hypotension • First dose ACEIs can induce dizziness, orthostatic hypotension, or even syncope in volume depleted, hyponatremic or exacerbated HF patients • First-dose response is related to increased pretreatment activity of RAA system • Concurrent diuretic therapy may increase the incidence of first-dose response in sensitive patients • Elderly & African American patients mostly have low renin hypertension & less responsive to ACEIs • Diuretic-ACEI combination overcome age- & race-related poor response

  50. ACE InhibitorsCompelling Indications • Heart Failure: ACEI (+diuretic) is considered fist-line & standard regimen in HTN+ systolic HF • Post-MI:ACEI+β-blocker showed reduction of CV risk independent of LV function & BP • High-Risk CHD: ACEIs must be early given in non-ST elevation MI & Unstable angina (as β-blocker) • In chronic angina: ACEI can be added after β-blocker or non-DHP CCB • DiabetesACEIs reduced hypertension-related CV events & nephropathy in diabetic (mostly type 2) patients (HOPE & UKPDS studies)

More Related